SECOND QUARTER IN BRIEF

  • Laquinimod eye drop phase I single ascending-dose part in healthy subjects was completed without reported safety concerns, multiple-dose part started
  • Active Biotech strengthened the patent protection for laquinimod in eye disorders (April 26)
  • FDA granted Orphan Drug Designation for tasquinimod in myelofibrosis (May 18)
  • Successful completion of the first stage of the phase IIa clinical study of naptumomab in combination with docetaxel, with the study now enrolling into the second stage (June 1)

EVENTS AFTER THE END OF THE PERIOD

  • The first part of the multiple-dose of laquinimod eye drops in the phase I study has been completed without any serious side effects that can be linked to laquinimod and the study has been expanded with another dose group
  • The board of directors resolved on August 4, 2022, based on the authorisation from the general meeting, to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs

Financial summary

SEK MApr-JunJan-JunFull-year

2022 20212022 20212021
Net sales-----
Operating profit/loss-14,0-12,6-29,3-22,4-49,8
Profit/loss after tax-14,3-12,6-30,0-22,4-49,8
Earnings per share (SEK)-0,07-0,06-0,14-0,11-0,24
Cash and cash equivalents (at close of period)

21,978,553,1

The report is also available at www.activebiotech.com.

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

This information is information that Active Biotech is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-08-04 08:15 CEST.

Attachments

220804 Active Biotech Interim Report Q2

© Modular Finance, source Nordic Press Releases